Advertisement
Advertisement
U.S. markets open in 1 hour 29 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Immutep Limited (IMMP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.2300-0.0500 (-2.19%)
At close: 04:00PM EDT
2.2700 +0.04 (+1.79%)
After hours: 04:36PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close2.2800
Open2.2500
Bid2.0000 x 1000
Ask0.0000 x 800
Day's Range2.2000 - 2.2700
52 Week Range1.8500 - 5.0000
Volume22,796
Avg. Volume106,720
Market Cap193.175M
Beta (5Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-0.2400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.19
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IMMP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Immutep Limited
    Daily – Vickers Top Insider Picks for 07/19/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    20 days agoArgus Research
View more
  • Benzinga

    Immutep's Lung Cancer Candidate Shows Encouraging Efficacy As Second-Line Treatment

    Immutep Limited (NASDAQ: IMMP) announced new interim data from 2nd line non-small cell lung cancer (NSCLC) patients (Part B) in the Phase 2 TACTI-002 trial. Part B evaluates Immutep's lead product candidate, eftilagimod alpha (efti or IMP321), in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in 36 patients. Median overall survival (OS) was 9.7 months for those who received chemo-free therapy of efti in combination with pembrolizumab, comparable with the current standard

  • GlobeNewswire

    Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

    Encouraging efficacy results continue for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC)Patients in this 2nd line setting had confirmed disease progression on anti-PD-1 / anti-PD-L1 (“PD-X”) based 1st line therapy1Key facts reported: Median Overall Survival (OS) from therapy with efti in combination with pembrolizumab is 9.7 months25% were progression free at 6 months and 36.5% were alive at 18 months2 Chemo-free therapy of efti in combination with pembrolizumab contin

  • GlobeNewswire

    Immutep Quarterly Activities Report

    Phase II TACTI-002 trial met its primary objective in 1st line non-small cell lung cancer (NSCLC) patients, with 38.6% Overall Response Rate and favourable anti-tumour activityBiomarker and multivariate analysis data from the completed Phase IIb AIPAC trial reported, confirming efti is activating the immune system and helping patients live longerFour world leading oncologists join the Clinical Advisory BoardWell-funded with ~$80 million in cash, giving Immutep an expected cash runway into early

Advertisement
Advertisement